EGFR – Non-small cell lung cancer – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Patients with Non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation are a particular group of individuals. The etiology of cancer, the clinicopathological features, prognosis, and treatment paradigms are different from other NSCLC patients. EGFR mutations occur in 40%–60% of South-East Asian patients or 10%–20% of Caucasian patients with lung adenocarcinomas. Most EGFR mutation-positive tumors are in patients who were never smokers or light smokers, but the observation is not exclusive. Due to an increasing prevalence of non-smoking behavior, more female patients have EGFR mutations than male patients. In the Iressa Pan Asian Survival Study (IPASS) trial that accrued Asian non- or never smoking lung adenocarcinoma patients, 80% of the subjects were female. In this trial, 60% of the tumors harbored EGFR mutations.

 

The competitive landscape of EGFR – Non-small cell lung cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of EGFR – Non-small cell lung cancer across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

EGFR – Non-small cell lung cancer Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: EGFR – Non-small cell lung cancer – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Patritumab Deruxtecan  Daiichi Sankyo Co., Ltd. Phase 2

2          Thymalfasin      SciClone Pharmaceuticals         Phase 2

3          DZD9008          Dizal Pharmaceuticals   Phase 2

4          Osimertinib       Parexel Phase 2

5          INC280 (capmatinib)      Novartis Pharmaceuticals          Phase 2

6          AC0010            Acea Bio (Hangzhou) Co., Ltd.   Phase 2

7          Befotertinib and Icotinib Betta Pharmaceuticals Co., Ltd. Phase 2

8          G1T38 and Osimertinib  G1 Therapeutics, Inc.    Phase 2

9          Almonertinib      Jiangsu Hansoh Pharmaceutical Co., Ltd.            Phase 3

10        Erlotinib            Hoffmann-La Roche      Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Nephroblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
 Wilms' Tumor or Nephroblastoma is a rare malignant renal tumor that typically affects children, characterized by abnormal proliferation of cells that resemble embryonic kidney cells (metanephroma), leading to the term embryonal tumor. It mainly affects young children between the ages of 1 and 5 years, although it can occur before the age of 1 year or after the age of 8 years. Adult forms are very rare. The tumor is usually present as an abdominal mass, which is frequently unilateral. Other symptoms may include abdominal pain, hypertension, fever, hematuria, and anemia. The disease progresses rapidly, with regional dissemination in the retroperitoneal space, lymph nodes, vessels (renal vein and inferior vena cava), and the peritoneal cavity in cases of tumor effraction, with a high likelihood of metastases in the lungs and liver. Nephroblastoma is sporadic in 99% of cases, with 10% of these cases associated with congenital anomalies or specific syndromes. Genetic anomalies have bee
Read more

Onychomycosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Onychomycosis is a fungal infection of the toenails or fingernails that can involve any component of the nail unit, including the matrix, bed, and plate. It is a common disorder that may be a reservoir for infection resulting in significant medical problems. Moreover, onychomycosis can substantially influence one’s quality of life. It affects approximately 2% to 26% of different populations worldwide. It represents 20% to 50% of onychopathies and about 30% of cutaneous fungal infections. The chronic, long-lasting disease may result in nail dystrophy and lead to pain, absence from work, and decreased quality of life, as the dermatophyte can contaminate communal bathing facilities and spread to others. The primary aim of onychomycosis treatment is to cure the infection and prevent relapse. Both topical and oral agents are available to treat fungal nail infections. Generally, systemic therapy for onychomycosis is more successful than topical treatment, likely due to poor penetration of t
Read more

Acromegaly – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. Acromegaly may also cause thickening of the body's soft tissues, including the heart, lips, and tongue. When the disease affects children prior to the end of puberty, excess growth hormone can lead to accelerated growth and tall stature, known as gigantism. Acromegaly affects between 3 and 14 people out of every 100,000. Thelansis’s “Acromegaly Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acromegaly treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and Chin
Read more